The label clears 812.5. The flyer doesn't.

An investigational device ships to a clinical site with a label that says exactly what 21 CFR 812.5 requires: the caution statement, the manufacturer’s name and place of business, the hazards and contraindications the rule makes mandatory. The label is correct, the file is clean. A week later, the sponsor’s business-development team sets the same device out on a table at a trade show with a glossy one-pager describing how well it performs, and the company has just violated a different rule — one the label itself could never have satisfied, because 21 CFR 812.7 does not regulate what the label says. It regulates what everyone around the device is allowed to do.

What 812.5 actually requires

The labeling rule is specific and mostly mechanical. The device’s label must carry a caution statement identifying it as an investigational device limited by federal law to investigational use, the manufacturer’s or distributor’s name and place of business, and — where appropriate — the quantity of contents. The labeling has to describe the relevant contraindications, hazards, adverse effects, interfering substances or devices, warnings, and precautions, and it may not contain any false or misleading statement. One prohibition sits inside 812.5 itself, not as an afterthought: the labeling may not represent that the device is safe or effective for the purposes under investigation. That is the label’s own ceiling, and a compliant label stays under it.

What 812.7 separately bars

812.7 is not a labeling rule at all. It is a conduct rule, binding the sponsor, the investigator, and anyone acting for either of them, and it runs on its own four prohibitions. They may not promote or test-market the device before FDA has authorized it for commercial distribution. They may not commercialize it by charging more than what recovers the cost of manufacture, research, development, and handling. They may not unduly prolong the investigation — and if the data in hand show a Class III device cannot justify premarket approval, or a Class II device will not meet an applicable performance standard, the sponsor has to terminate the study promptly rather than let it run. And separately from anything printed on the device itself, they may not represent, in any communication, that the device is safe or effective for the purposes being investigated. None of that four-part list asks what the label says.

Where the two rules diverge in practice

FDA’s own 1999 guidance on recruiting investigators and subjects exists precisely because a sponsor still has to tell people an investigational device exists without crossing into promotion — and it draws the line around conduct a compliant label never touches: announcements limited to scientific or medical channels rather than general audiences, notices that stick to how to apply as an investigator or how to obtain the device for study use, and no claim, anywhere in that notice, implying the device is reliable or effective ahead of the finding that would actually establish it. A conference booth, a sales call, a recruitment email, and an investor pitch deck are four different places a compliant 812.5 label will never appear to save them.

The label is a compliance document. 812.7 is a conduct rule, and conduct does not show up on a page.

The practice

Treat the label sign-off and the promotion review as two separate approvals, assigned to whoever is actually positioned to catch each one — regulatory affairs for the label’s content, and a second, deliberate review for marketing materials, trade show plans, and investigator-recruitment notices before they go out. A label that passed 812.5 review is evidence of nothing when the question is whether a conference handout or a recruitment flyer crossed into promotion under 812.7. They are different rules, read by different people, and a study’s compliance record should show both reviews happened, not just one.

This is regulatory intelligence and method, not a determination about any specific device, study, or piece of marketing material — whether a given communication crosses into promotion under 812.7 is a judgment for your regulatory and clinical teams, working from the actual facts.